接受多轮粪便免疫化学检测受试者的间期结直肠癌发生率
该研究分析了荷兰2006至2014年基于粪便免疫化学检测(FIT)的每两年一次结直肠癌筛查试点项目数据,共邀请27304人,18716人至少参与一次。共检出261例结直肠癌,其中筛查检出116例,非筛查检出145例(含27例FIT间期癌、9例结肠镜间期癌和109例未参与者癌症);完成3轮筛查后FIT间期癌比例为23%。
要点
- 完成3轮FIT筛查后FIT间期癌比例为23%,即FIT对结直肠癌的敏感性为77%。
- 筛查检出结直肠癌者早期肿瘤比例高于非筛查检出者(P < .001)。
- 筛查检出者和FIT间期癌者生存率分别为89%和81%,高于结肠镜间期癌者44%和未参与者癌症者60%(P < .001)。
核心结论
- 在基于FIT的每两年一次筛查试点项目中,接受FIT筛查者中23%发生FIT间期癌,FIT对结直肠癌的敏感性为77%。
- FIT筛查中间期癌的比例似乎低于愈创木脂粪便隐血试验。
研究设计与样本
- 荷兰2006至2014年基于FIT的每两年一次结直肠癌筛查试点项目数据分析。
- 共邀请27304名合格个体,其中18716人(69%)至少参与一次;3005人(16%)在4轮筛查中有一轮FIT结果阳性。
- FIT阴性者收到说明粪便样本未检测到血液的信件,符合条件者每两年再次受邀筛查;FIT阳性者(血红蛋白浓度10 μg Hb/g粪便)受邀咨询并安排结肠镜。
- 第四轮FIT筛查后,队列与荷兰癌症登记处链接至2015年3月31日,收集所有结直肠癌病例的参与者特征、肿瘤分期、部位和生存状态。
- 参照组为同期荷兰普通人群中年龄50-76岁、未接受结直肠癌筛查的结直肠癌患者。
主要发现
- 共261名参与者检出结直肠癌:筛查检出结直肠癌116例,非筛查检出结直肠癌145例(FIT间期癌27例、结肠镜间期癌9例、未参与者结直肠癌109例)。
- 完成3轮筛查后FIT间期癌比例为23%。
- 筛查检出结直肠癌者早期肿瘤多于非筛查检出结直肠癌者(P < .001)。
- 筛查检出结直肠癌者和FIT间期癌者生存率分别为89%和81%,高于结肠镜间期癌者(44%生存率)和未参与者结直肠癌者(60%生存率)(P < .001)。
关键数值与推荐
- FIT阳性阈值:血红蛋白浓度10 μg Hb/g粪便。
- 两次邀请之间的中位时间2.37年用作FIT间期癌分类截断值。
- 完成3轮筛查后FIT间期癌比例为23%,FIT对结直肠癌的敏感性为77%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Among subjects screened for colorectal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop in 48% to 55% of the subjects. Data are limited on how many persons screened by fecal immunochemical tests (FIT), over multiple rounds, develop interval cancers. In the Netherlands, a pilot FIT-based biennial CRC screening program was conducted between 2006 and 2014. We collected and analyzed data from the program on CRCs detected during screening (SD-CRC) and CRCs not detected within the screening program (non-SD-CRC; such as FIT interval cancers, colonoscopy interval cancers, and cancer in nonparticipants). METHODS: Screenees with a negative FIT result received a letter explaining that no blood had been detected in the stool sample and were re-invited, if eligible, for screening biennially. Screenees with a positive FIT result (hemoglobin concentration of 10 μg Hb/g feces) were invited for consultation and scheduled for colonoscopy; results were collected. After the fourth round of FIT screening, the cohort was linked to the Netherlands Cancer Registry, through March 31, 2015; participant characteristics, data on tumor stage, location (at time of resection), and survival status were collected for all identified CRC cases. A reference group comprised all persons with CRC diagnosed in the Netherlands general population during the same period, in the same age range (50-76 years), who had not been offered CRC screening. The median time between invitations (2.37 years) was used as a cutoff to categorize participants within the FIT interval cancer category. We compared participant characteristics, tumor characteristics, and mortality among subjects with SD-CRC and with non-SD-CRC. RESULTS: A total of 27,304 eligible individuals were invited for FIT screening, of whom 18,716 (69%) participated at least once. Of these, 3005 (16%) had a positive result from the FIT in 1 of the 4 screening rounds. In total, CRC was detected in 261 participants: 116 SD-CRCs and 145 non-SD-CRCs (27 FIT interval cancers, 9 colonoscopy interval cancers, and 109 CRCs in nonparticipants). The FIT interval cancer proportion after 3 completed screening rounds was 23%. Participants with SD-CRC had more early-stage tumors than participants with non-SD-CRCs (P < .001). Of persons with SD-CRC and FIT interval cancers, significantly higher proportions survived (89% and 81%, respectively) compared with persons with colonoscopy interval cancers (44% survival) and nonparticipants with CRC (60% survival) (P < .001). CONCLUSIONS: In an analysis of data from a pilot FIT-based biennial screening program, we found that among persons screened by FIT, 23% developed FIT interval cancer. FIT therefore detects CRC with 77% sensitivity. The proportion of FIT interval cancers in FIT screening appears to be lower than that with guaiac fecal occult blood testing. Clinical trial registry: yes, www.trialregister.nl, trial number: NTR5385.
引用
- van der Vlugt M, Grobbee EJ, Bossuyt PMM, et al. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing. Gastroenterology. 2017. PMID: 28483499. doi:10.1053/j.gastro.2017.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。